Showing 1 - 2 results of 2 for search 'Tom van Meerten', query time: 0.01s
Refine Results
-
1
K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies by Nienke Visser, Macarena González-Corrales, Jimena Álvarez-Freile, Maurien G. Pruis, Lena Rockstein, Harm Jan Lourens, Jan Jacob Schuringa, Tom van Meerten, Gerwin Huls, Edwin Bremer
Published 2025-06-01Get full text
Article -
2
T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines by Cilia R. Pothast, Quincy Hofsink, Sabine Haggenburg, Romy C. Dijkland, Marian van de Meent, Kayleigh van Dijk, Michel S. Bhoekhan, Nienke J.E. Haverkate, Johan van Meerloo, J.H. Frederik Falkenburg, Ruben A.L. de Groen, Annoek E.C. Broers, Jaap A. van Doesum, Rob S. van Binnendijk, Gerco den Hartog, Birgit I. Lissenberg-Witte, Arnon P. Kater, Gaby P. Smits, Dorine Wouters, Ester M.M. van Leeuwen, Hetty J. Bontkes, Neeltje A. Kootstra, Sandra Vogels-Nooijen, Debbie van Baarle, Rory D. de Vries, Tom van Meerten, Pim G.N.J. Mutsaers, Abraham Goorhuis, Inger S. Nijhof, Mette D. Hazenberg, Mirjam H.M. Heemskerk, Caroline E. Rutten, COBRA KAI study team
Published 2025-05-01Get full text
Article